Your browser doesn't support javascript.
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Grever, Michael; Andritsos, Leslie; Banerji, Versha; Barrientos, Jacqueline C; Bhat, Seema; Blachly, James S; Call, Timothy; Cross, Matthew; Dearden, Claire; Demeter, Judit; Dietrich, Sasha; Falini, Brunangelo; Forconi, Francesco; Gladstone, Douglas E; Gozzetti, Alessandro; Iyengar, Sunil; Johnston, James B; Juliusson, Gunnar; Kraut, Eric; Kreitman, Robert J; Lauria, Francesco; Lozanski, Gerard; Parikh, Sameer A; Park, Jae; Polliack, Aaron; Ravandi, Farhad; Robak, Tadeusz; Rogers, Kerry A; Saven, Alan; Seymour, John F; Tadmor, Tamar; Tallman, Martin S; Tam, Constantine S; Tiacci, Enrico; Troussard, Xavier; Zent, Clive; Zenz, Thorsten; Zinzani, Pier Luigi; Wörmann, Bernhard.
  • Grever M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Michael.grever@osumc.edu.
  • Andritsos L; Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
  • Banerji V; Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Barrientos JC; Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
  • Bhat S; Department of Medicine, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Feinstein Institute for Medical Research, New York, NY, USA.
  • Blachly JS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
  • Call T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
  • Cross M; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Dearden C; Royal Marsden Hospital, London, UK.
  • Demeter J; Royal Marsden Hospital, London, UK.
  • Dietrich S; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
  • Falini B; Department of Hematology, University Hospital, Heidelberg, Germany.
  • Forconi F; Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy.
  • Gladstone DE; Cancer Sciences and Haematology Department, University of Southampton Hospital Trust, Southampton, UK.
  • Gozzetti A; Johns Hopkins University, Baltimore, MD, USA.
  • Iyengar S; University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
  • Johnston JB; Royal Marsden Hospital, London, UK.
  • Juliusson G; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • Kraut E; Stem Cell Centre, Department of Laboratory Medicine, Lund University, and Department of Hematology, Skåne University Hospital, Lund, Sweden.
  • Kreitman RJ; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
  • Lauria F; Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
  • Lozanski G; University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
  • Parikh SA; Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
  • Park J; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Polliack A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ravandi F; Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Robak T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rogers KA; Department of Hematology, Medical University of Lodz, Lodz, Poland.
  • Saven A; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
  • Seymour JF; Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
  • Tadmor T; Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Tallman MS; Hematology Unit, Bnai-Zion Medical Center and Rappaport Faculty of Medicine, Technion Institute Technology, Haifa, Israel.
  • Tam CS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tiacci E; Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Troussard X; Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy.
  • Zent C; Department of Hematology, Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
  • Zenz T; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Zinzani PL; Department of Medical Oncology and Haematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
  • Wörmann B; IRCCS Azienda Ospedaliero-Universitaria di Bologna and Instituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy.
Leukemia ; 35(7): 1864-1872, 2021 07.
Article in English | MEDLINE | ID: covidwho-1216445
Semantic information from SemMedBD (by NLM)
1. hydrochloride CAUSES treatment options
Subject
hydrochloride
Predicate
CAUSES
Object
treatment options
2. Patient observation TREATS Patients
Subject
Patient observation
Predicate
TREATS
Object
Patients
3. hydrochloride CAUSES treatment options
Subject
hydrochloride
Predicate
CAUSES
Object
treatment options
4. Patient observation TREATS Patients
Subject
Patient observation
Predicate
TREATS
Object
Patients
ABSTRACT
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Hairy Cell / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Leukemia Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S41375-021-01257-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Hairy Cell / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Leukemia Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S41375-021-01257-7